Personalised Cancer Therapeutics. Intelligently Designed.

Technology pioneered at the Mount Sinai School of Medicine

Working with

PDP current logo 23 Aug 2019 copy.jpg
PDP .jpg

The Personal Discovery Process provides individuals with treatment-driven research on an unprecedented scale. Our Personal Discovery Process (PDP) is effectively a massive clinical trial for a single patient. We engineer the genetic complexity of each patient's unique tumour network into an army of 400,000 fruit fly "avatars". Using robotics, we evaluate up to 1,800 FDA approved drugs including non-cancer drugs, to identify drug combinations that are efficacious in the individual's avatar population.

The Icahn School of Medicine at Mount Sinai developed the PDP methodology over years of clinical research, with technical input from the FDA. They found that real-world patient tumours are made resistant to single drug treatments by mutations in several genes, including genes not previously associated with cancer. Such resistant tumours can, however, be effectively addressed with novel combinations of FDA approved drugs. The most effective combinations almost always include non-cancer drugs. The PDP methods are licensed exclusively to My Personal Therapeutics.

As featured in


Learn More

Backed by


Where you can meet us next

Oncology Convention Birmingham 2020 November 9 - 10

DEVELOPMENT OF PERSONALISED TREATMENT RECOMMENDATIONS FOR COLORECTAL CANCER PATIENTS

Ready to get started?

Contact us now and we'll get you started